Last 7 days
-0.9%
Last 30 days
9.0%
Last 90 days
34.4%
Trailing 12 Months
106.4%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 9.7M | 10.3M | 10.2M | 10.0M |
2021 | 8.8M | 9.5M | 9.9M | 10.3M |
2020 | 0 | 0 | 0 | 8.6M |
2019 | 0 | 0 | 0 | 0 |
2018 | 0 | 0 | 0 | 0 |
2017 | 2.5M | 2.8M | 3.3M | 0 |
2016 | 2.0M | 1.9M | 2.1M | 2.3M |
2015 | 1.8M | 1.9M | 1.8M | 1.9M |
2014 | 1.7M | 1.6M | 1.6M | 1.7M |
2013 | 1.8M | 2.1M | 1.9M | 1.7M |
2012 | 2.1M | 1.7M | 1.9M | 1.8M |
2011 | 2.6M | 2.5M | 2.2M | 2.2M |
2010 | 2.7M | 2.8M | 2.9M | 2.9M |
2009 | 0 | 0 | 0 | 2.7M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 15, 2023 | banks robert r. jr. | bought | 3,206 | 1.6869 | 1,901 | president and ceo |
Aug 14, 2023 | banks robert r. jr. | bought | 148 | 1.5 | 99.00 | president and ceo |
Jan 05, 2023 | harris joseph michael | acquired | - | - | 8,402 | - |
Jan 05, 2023 | amron arthur h | acquired | - | - | 27,613 | - |
Jan 05, 2023 | lask alisa | acquired | - | - | 27,613 | - |
Jan 05, 2023 | gwydir tom | acquired | - | - | 27,613 | - |
Jan 05, 2023 | spandow oliver j. | acquired | - | - | 42,481 | - |
Mar 05, 2022 | astor andrew | acquired | 40,000 | 2.7 | 14,815 | president, ceo & cfo |
Feb 16, 2022 | lobo wesley s. | sold (taxes) | -30,667 | 4.8 | -6,389 | chief marketing officer |
Dec 14, 2021 | gwydir tom | acquired | - | - | 4,582 | - |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Nov 15, 2023 | MORGAN STANLEY | unchanged | - | -1,071 | 22,632 | -% |
Nov 14, 2023 | STATE STREET CORP | unchanged | - | -863 | 23,469 | -% |
Nov 14, 2023 | Tower Research Capital LLC (TRC) | reduced | -59.21 | -525 | 334 | -% |
Nov 14, 2023 | WEXFORD CAPITAL LP | added | 0.82 | -211,663 | 5,457,410 | 1.21% |
Nov 14, 2023 | VANGUARD GROUP INC | added | 3.9 | -2,008 | 252,654 | -% |
Nov 14, 2023 | Royal Bank of Canada | sold off | -100 | - | - | -% |
Nov 14, 2023 | JPMORGAN CHASE & CO | new | - | 12.00 | 12.00 | -% |
Nov 14, 2023 | RENAISSANCE TECHNOLOGIES LLC | sold off | -100 | -21,000 | - | -% |
Nov 13, 2023 | WELLS FARGO & COMPANY/MN | added | 3.03 | -1.00 | 101 | -% |
Nov 13, 2023 | ELKHORN PARTNERS LIMITED PARTNERSHIP | unchanged | - | -3,000 | 67,000 | 0.04% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 03, 2023 | cowen prime advisors llc | - | 0 | SC 13G | |
Feb 03, 2023 | cowen prime advisors llc | - | 0 | SC 13G | |
Feb 03, 2023 | cowen prime advisors llc | 4.00% | 1,431,404 | SC 13G | |
Jan 06, 2023 | intelligent fanatics capital management llc | 0% | 0 | SC 13G/A | |
Feb 28, 2022 | intelligent fanatics capital management llc | 5.12% | 525,408 | SC 13G | |
Feb 09, 2022 | cowen prime advisors llc | 6% | 633,050 | SC 13G | |
Feb 08, 2022 | samjo capital llc | 4.2% | 425,000 | SC 13G/A | |
Jun 11, 2021 | evans daron | 4.7% | 478,874 | SC 13D/A | |
Jan 27, 2021 | cowen prime services llc | 6% | 575,077 | SC 13G | |
Oct 26, 2020 | wexford capital lp | 36.78% | 6,664 | SC 13D/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Nov 08, 2023 | 10-Q | Quarterly Report | |
Nov 06, 2023 | 8-K | Current Report | |
Nov 03, 2023 | 4 | Insider Trading | |
Nov 03, 2023 | 3 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.9B | 40.0B | 10.31% | -2.25% | 35.24 | 4.55 | -11.26% | -34.57% |
BDX | 71.3B | 19.4B | -9.23% | -5.96% | 44.09 | 3.79 | 2.66% | -16.58% |
BAX | 18.3B | 15.0B | 6.14% | -30.83% | 7.06 | 1.22 | 3.01% | 209.09% |
ALGN | 16.9B | 3.8B | 14.26% | 16.16% | 46.7 | 4.45 | -1.48% | -28.97% |
MID-CAP | ||||||||
HSIC | 9.3B | 12.7B | 13.37% | -11.57% | 21 | 0.74 | 0.68% | -30.25% |
BIO | 8.9B | 2.7B | -0.34% | -27.61% | -55.55 | 3.25 | -3.01% | 97.36% |
ATR | 8.4B | 3.4B | 1.77% | 17.97% | 29.76 | 2.43 | 3.13% | 18.17% |
XRAY | 6.8B | 3.9B | 15.17% | 5.28% | -30.97 | 1.72 | -2.62% | 73.28% |
AXNX | 2.9B | 342.6M | 7.33% | -13.77% | -240.35 | 8.4 | 42.19% | 84.14% |
PDCO | 2.5B | 6.6B | -12.19% | -8.47% | 12.51 | 0.38 | 2.61% | 0.62% |
SMALL-CAP | ||||||||
AHCO | 1.1B | 3.1B | 27.38% | -62.38% | -2.62 | 0.36 | 7.95% | -550.16% |
ANIK | 328.7M | 163.3M | 8.29% | -28.40% | -13.38 | 2.01 | 7.14% | -56.09% |
ANGO | 279.9M | 335.9M | 9.78% | -43.73% | 43.42 | 0.83 | 4.71% | 116.39% |
APYX | 73.4M | 50.3M | 2.42% | 10.99% | -4.85 | 1.46 | 3.23% | 20.81% |
AEMD | 5.0M | 3.8M | 4.66% | -47.56% | -0.43 | 1.32 | 17.30% | 10.67% |
Income Statement (Quarterly) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Revenue | 4.9% | 2,526,500 | 2,409,000 | 2,884,000 | 2,187,000 | 2,675,000 | 2,578,000 | 2,266,000 | 2,736,000 | 2,334,000 | 2,121,000 | 1,577,000 | 2,529,000 | 2,107,667 | 1,686,333 | 1,265,000 | 843,667 | 422,333 | 1,000 | 1,000 | 306,000 | 611,000 |
Gross Profit | 98.8% | 1,515,000 | 762,000 | 1,395,000 | 1,053,000 | 1,441,000 | 1,360,000 | 1,275,000 | 1,587,000 | 1,302,000 | 1,225,000 | 895,000 | 1,491,000 | 1,900,000 | 1,819,000 | 1,367,000 | 998,000 | 954,000 | 952,000 | 830,000 | 467,000 | 788,000 |
Operating Expenses | 8.1% | 2,208,000 | 2,043,000 | 2,209,000 | 2,600,000 | 1,959,000 | 2,162,000 | 2,392,000 | 2,605,000 | 2,021,000 | 2,157,000 | 2,493,000 | 2,517,000 | 2,191,000 | 2,514,000 | 2,235,000 | 2,299,000 | 1,683,000 | 1,463,000 | 1,483,000 | 1,590,000 | 1,191,000 |
S&GA Expenses | 2.6% | 1,787,500 | 1,743,000 | 1,885,000 | 2,177,000 | 1,723,000 | 1,718,000 | 1,854,000 | 1,999,000 | 1,362,000 | 1,544,000 | 1,610,000 | 1,950,000 | 1,426,000 | 1,787,000 | 1,403,000 | 1,503,000 | 1,097,000 | 1,069,000 | 1,091,000 | 1,260,000 | 894,000 |
R&D Expenses | 42.3% | 358,500 | 252,000 | 273,000 | 372,000 | 194,000 | 395,000 | 487,000 | 556,000 | 609,000 | 751,000 | 836,000 | 563,000 | 764,000 | 777,000 | 793,000 | 756,000 | - | 352,000 | - | - | - |
EBITDA Margin | - | - | - | - | - | - | -0.43 | -0.45 | -0.48 | -0.49 | -0.33 | -0.29 | -0.27 | -0.29 | -0.35 | -0.42 | -0.48 | -0.54 | - | - | - | - |
Interest Expenses | -25.0% | 3,000 | 4,000 | 6,000 | 7,000 | 7,000 | 10,000 | 11,000 | 13,000 | 15,000 | 22,000 | 30,000 | 43,000 | 55,000 | 48,000 | 46,000 | 46,000 | 26,000 | 32,000 | 28,000 | 86,000 | 84,000 |
Income Taxes | - | - | - | - | - | 37,000 | 7,000 | 14,000 | 21,000 | 1,000 | - | 10,000 | 11,000 | -229,000 | - | - | - | -100,000 | 4,000 | - | 3,000 | -1,795,000 |
EBT Margin | - | - | - | - | - | - | -0.45 | -0.48 | -0.52 | -0.53 | -0.36 | -0.33 | -0.31 | -0.33 | -0.39 | -0.46 | -0.53 | -0.60 | - | - | - | - |
Net Income | 78.1% | -706,500 | -3,231,000 | -1,137,000 | -1,967,000 | -922,500 | -1,222,000 | -1,126,000 | -537,000 | -759,000 | -1,012,000 | -1,657,000 | -1,098,000 | -144,000 | -744,000 | -942,000 | -1,349,000 | -725,000 | -566,000 | -682,000 | -1,429,000 | 1,289,000 |
Net Income Margin | -2.7% | -0.71 | -0.69 | -0.50 | -0.54 | -0.37 | -0.36 | -0.36 | -0.45 | -0.53 | -0.42 | -0.36 | -0.27 | -0.31 | - | - | - | - | - | - | - | - |
Free Cashflow | -14.7% | -195,000 | -170,000 | -1,175,000 | -1,831,000 | -335,000 | -923,000 | -117,000 | -78,000 | -1,526,000 | -1,830,000 | -1,946,000 | -1,840,000 | 364,000 | - | - | - | - | - | - | - | - |
Balance Sheet | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | 5.1% | 10,919 | 10,386 | 10,927 | 10,999 | 11,335 | 14,953 | 15,528 | 17,650 | 17,820 | 17,991 | 17,936 | 18,510 | 15,242 | 16,649 | 18,294 | 11,629 | 11,554 | 12,014 | 10,138 | 10,558 | 9,404 |
Current Assets | 7.5% | 8,506 | 7,914 | 8,324 | 8,261 | 9,118 | 11,122 | 11,657 | 13,634 | 13,621 | 14,840 | 14,667 | 15,154 | 11,755 | 13,070 | 14,809 | 8,299 | 8,117 | 8,437 | 7,172 | 8,173 | 8,376 |
Cash Equivalents | 13.8% | 4,622 | 4,060 | 3,836 | 3,634 | 3,940 | 4,179 | 5,421 | 6,973 | 7,350 | 8,278 | 8,163 | 8,249 | 5,155 | 7,046 | 8,962 | 4,166 | 3,855 | 4,318 | 3,608 | 4,581 | 5,322 |
Inventory | 6.7% | 2,268 | 2,126 | 2,348 | 3,153 | 3,488 | 4,664 | 4,679 | 4,462 | 4,649 | 5,087 | 4,679 | 5,304 | 5,385 | 4,769 | 3,649 | 2,562 | 2,128 | 2,314 | 2,040 | 1,864 | 1,459 |
Net PPE | -10.2% | 88.00 | 98.00 | 107 | 116 | 128 | 450 | 384 | 72.00 | 382 | 303 | 311 | 295 | 302 | 296 | 76.00 | 81.00 | 85.00 | 89.00 | 97.00 | 91.00 | 20.00 |
Goodwill | 0% | 759 | 759 | 759 | 800 | 759 | 800 | 800 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 759 | 748 | - |
Liabilities | 32.7% | 2,297 | 1,731 | 2,033 | 2,118 | 1,754 | 2,472 | 2,126 | 2,901 | 2,490 | 3,000 | 2,399 | 2,937 | 3,802 | 4,373 | 4,658 | 3,940 | 4,832 | 5,208 | 4,534 | 3,760 | 2,337 |
Current Liabilities | 52.7% | 1,828 | 1,197 | 1,415 | 1,412 | 1,551 | 2,111 | 1,748 | 2,390 | 1,823 | 2,170 | 1,408 | 1,325 | 2,379 | 2,765 | 3,108 | 2,428 | 3,116 | 3,292 | 3,110 | 2,654 | 1,440 |
Shareholder's Equity | -0.4% | 8,622 | 8,655 | 8,894 | 5,592 | 6,302 | 12,481 | 13,402 | 14,749 | 15,330 | 14,991 | 15,537 | 15,573 | 11,440 | 12,276 | 13,636 | 7,689 | 6,722 | 6,806 | 5,604 | 6,798 | 4,067 |
Retained Earnings | -0.1% | -143,800 | -143,600 | -143,100 | -142,831 | -141,983 | -138,800 | -137,692 | -135,725 | -134,683 | -133,500 | -132,395 | -131,858 | -131,100 | -130,087 | -128,430 | -127,332 | -127,188 | -126,444 | -125,502 | -124,153 | -123,489 |
Additional Paid-In Capital | 0.1% | 152,364 | 152,215 | 152,021 | 148,413 | 148,275 | 148,040 | 147,781 | 147,346 | 146,883 | 145,378 | 144,801 | 144,296 | 139,410 | 139,243 | 138,953 | 131,934 | 130,830 | 130,169 | 127,974 | 127,873 | 127,419 |
Shares Outstanding | 0% | 10,485 | 10,485 | 10,485 | 10,297 | 10,304 | 10,299 | 10,214 | 10,258 | 10,045 | 9,943 | 9,883 | 9,873 | 9,040 | 8,986 | 8,590 | 8,059 | 7,409 | 7,259 | 7,130 | 7,185 | 6,751 |
Minority Interest | - | - | - | - | 3,289 | 3,279 | 3,260 | 3,242 | 3,054 | 3,054 | 3,054 | 3,053 | 3,051 | 3,052 | 3,046 | 3,040 | 3,014 | 3,009 | 3,003 | 3,000 | 3,000 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | 148.7% | 562,000 | 226,000 | 276,000 | -195,000 | -170,000 | -1,072,000 | -1,797,000 | -335,000 | -910,000 | -117,000 | -55,000 | -1,526,000 | -1,817,000 | -1,720,000 | -1,840,000 | 364,000 | -614,000 | -1,329,000 | -697,000 | -528,000 | -1,122,000 |
Share Based Compensation | -23.2% | 149,000 | 194,000 | 319,000 | 179,000 | 254,000 | 277,000 | 272,000 | 434,000 | 268,000 | 281,000 | 276,000 | 206,000 | 172,000 | 179,000 | 222,000 | 670,000 | 354,000 | 150,000 | 158,000 | 397,000 | 120,000 |
Cashflow From Investing | - | - | - | - | - | - | -103,000 | -34,000 | - | -62,000 | - | -23,000 | - | -13,000 | - | - | - | -14,000 | - | -137,000 | - | - |
Cashflow From Financing | 100.0% | - | -2,000 | -74,000 | -111,000 | -69,000 | -67,000 | 281,000 | -37,000 | 46,000 | 231,000 | -3,000 | 4,615,000 | -65,000 | 28,000 | 6,638,000 | -55,000 | 171,000 | 2,038,000 | -137,000 | 778,000 | 2,960,000 |
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Net revenue: | ||||
Total net revenues | $ 3,742 | $ 2,409 | $ 10,984 | $ 7,417 |
Cost of goods sold | 1,548 | 1,647 | 4,600 | 4,195 |
Gross margin | 2,194 | 762 | 6,384 | 3,222 |
Operating expenses: | ||||
Selling, general and administrative | 2,137 | 1,743 | 6,500 | 5,806 |
Research and development | 205 | 252 | 665 | 896 |
Depreciation and amortization | 55 | 48 | 163 | 162 |
Total operating expenses | 2,397 | 2,043 | 7,328 | 6,864 |
Operating loss from continuing operations | (203) | (1,281) | (944) | (3,642) |
Other (expense) income: | ||||
Interest expense | (4) | (1) | (17) | |
Interest income | 11 | 4 | 36 | 7 |
Other income (expense), net | 10 | 31 | (12) | 94 |
Total other expense: | 21 | 31 | 23 | 84 |
Loss from continuing operations | (182) | (1,250) | (921) | (3,558) |
Net loss from discontinued operations | (1,904) | (2,700) | ||
Net loss | (182) | (3,154) | (921) | (6,258) |
Less: Undeclared deemed dividend attributable to noncontrolling interest | (77) | (206) | ||
Net loss attributable to Nephros, Inc. shareholders | $ (182) | $ (3,231) | $ (921) | $ (6,464) |
Net loss per common share, basic from continuing operations | $ (0.02) | $ (0.12) | $ (0.09) | $ (0.35) |
Net loss per common share, diluted from continuing operations | (0.02) | (0.12) | (0.09) | (0.35) |
Net loss per common share, basic from discontinued operations | (0.18) | (0.26) | ||
Net loss per common share, diluted from discontinued operations | (0.18) | (0.26) | ||
Net loss per common share, basic | (0.02) | (0.30) | (0.09) | (0.61) |
Net loss per common share, diluted | (0.02) | (0.30) | (0.09) | (0.61) |
Net loss per common share, basic, attributable to continuing noncontrolling interest | (0.01) | (0.02) | ||
Net loss per common share, diluted, attributable to continuing noncontrolling interest | (0.01) | (0.02) | ||
Net loss per common share, basic, attributable to Nephros, Inc, shareholders | (0.02) | (0.31) | (0.09) | (0.63) |
Net loss per common share, diluted, attributable to Nephros, Inc, shareholders | $ (0.02) | $ (0.31) | $ (0.09) | $ (0.63) |
Weighted average common shares outstanding, basic | 10,460,866 | 10,303,818 | 10,352,108 | 10,278,258 |
Weighted average common shares outstanding, diluted | 10,460,866 | 10,303,818 | 10,352,108 | 10,278,258 |
Comprehensive loss: | ||||
Net loss | $ (182) | $ (3,154) | $ (921) | $ (6,258) |
Other comprehensive loss, foreign currency translation adjustments, net of tax | (3) | |||
Comprehensive loss | (182) | (3,154) | (921) | (6,261) |
Comprehensive loss attributable to noncontrolling interest | (77) | (206) | ||
Comprehensive loss attributable to Nephros, Inc. shareholders | (182) | (3,231) | (921) | (6,467) |
Product [Member] | ||||
Net revenue: | ||||
Total net revenues | 3,713 | 2,399 | 10,912 | 7,387 |
Royalty and Other Revenues [Member] | ||||
Net revenue: | ||||
Total net revenues | $ 29 | $ 10 | $ 72 | $ 30 |
Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 4,622 | $ 3,634 |
Accounts receivable, net | 1,443 | 1,286 |
Inventory | 2,268 | 3,153 |
Prepaid expenses and other current assets | 173 | 188 |
Total current assets | 8,506 | 8,261 |
Property and equipment, net | 88 | 116 |
Lease right-of-use assets | 750 | 984 |
Intangible assets, net | 392 | 423 |
Goodwill | 759 | 759 |
License and supply agreement, net | 301 | 402 |
Other assets | 123 | 54 |
TOTAL ASSETS | 10,919 | 10,999 |
Current liabilities: | ||
Current portion of secured note payable | 71 | |
Accounts payable | 805 | 740 |
Accrued expenses | 712 | 285 |
Current portion of lease liabilities | 311 | 316 |
Total current liabilities | 1,828 | 1,412 |
Equipment financing, net of current portion | 1 | |
Lease liabilities, net of current portion | 469 | 705 |
TOTAL LIABILITIES | 2,297 | 2,118 |
COMMITMENTS AND CONTINGENCIES (Note 14) | ||
STOCKHOLDERS’ EQUITY | ||
Preferred stock, $.001 par value; 5,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022. | ||
Common stock, $.001 par value; 40,000,000 shares authorized at September 30, 2023 and December 31, 2022; 10,484,932 and 10,297,429 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively. | 10 | 10 |
Additional paid-in capital | 152,364 | 148,413 |
Accumulated deficit | (143,752) | (142,831) |
Subtotal | 8,622 | 5,592 |
Noncontrolling interest | 3,289 | |
TOTAL STOCKHOLDERS’ EQUITY | 8,622 | 8,881 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 10,919 | $ 10,999 |
 CEO | Mr. Robert Banks |
---|---|
 WEBSITE | www.nephros.com |
 EMPLOYEES | 27 |